Ontario s Narcotics Strategy
|
|
- Ashlie Golden
- 5 years ago
- Views:
Transcription
1 Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference
2 Background The Need for Action Inappropriate use and abuse of prescription narcotics and other controlled substances is a serious public health and safety issue in Canada, the United States and elsewhere in the world. Issues include: excessive prescribing, escalating misuse, escalating diversion away from intended medical purposes, increases in addictions, increases in narcotics-related deaths Ontario has the highest rate of narcotics use in Canada Since 1991, prescriptions for oxycodone-containing products rose by 900% in Ontario Since 2004, the number of oxycodone-related deaths in Ontario has nearly doubled Recent studies suggest that increased rates of opioid prescribing, particularly long-acting oxycodone, is contributing significantly to morbidity and unintentional opioid-related mortality A number of First Nations communities have declared a state of emergency over the abuse of prescription narcotics, particularly oxycodone-containing drugs 2
3 Background Measures taken by the Ministry Established the Narcotics Advisory Panel in March member multi-disciplinary group with a mandate to provide recommendations to the Executive Officer of Ontario Public Drug Programs (OPDP) on appropriate prescribing, dispensing, and utilization related to opioids and pain management strategies Expertise from professional and regional perspectives, including physicians (family practice, specialists in pain and addiction), pharmacists, the Coroner's Office, professional regulatory bodies and law enforcement Developed a comprehensive narcotics strategy that considers the balance between the availability of narcotics to treat pain and preventing abuse 3
4 Overview of the Narcotics Strategy The Narcotics Strategy is intended to address misuse of prescription narcotics and other controlled substances, and to ensure their safe and appropriate use by patients with medical needs. The Narcotics Strategy aims to: promote awareness of inappropriate prescribing, dispensing and utilization promote appropriate prescribing and dispensing through education develop a proposal to expand treatment and support for addictions to narcotics and controlled substances There are five key elements to the Narcotics Strategy: new legislation to support the development of a narcotics monitoring database partnering with the health care sector to educate on appropriate prescribing partnering with the health care sector to educate on appropriate dispensing education to prevent excessive use of prescription narcotics and controlled substances treatment of addictions 4
5 Enactment of New Legislation A key component of the strategy was the introduction of the Narcotics Safety and Awareness Act, 2010 ("NSAA"). The NSAA and its regulation* will help to support the Government s ability to collect, use and disclose information, including personal health information, that relate to the prescribing and dispensing of prescription narcotic and controlled substance medications in Ontario. The law came into force on November 1, Effective November 1, 2011, the following additional requirements, among others, will be required for a prescription narcotic or controlled substance: For Patients: upon request, must provide an approved form of identification to their prescriber / dispenser to record as appropriate in order to receive a prescription for a narcotic or controlled substance approved forms of identification include health card, driver s licence, certificate of Indian Status, etc. The complete list is available on the ministry website at: spx *Note: Please see Appendix for summary of legislative requirements 5
6 Enactment of New Legislation For Prescribers: Must record all of the following information on the prescription: Identification number of the patient and the type of identification used Registration number on the certificate of registration issued to the prescriber by the College of which he or she is a member Name of the person for whom the monitored drug is prescribed Name, strength (where applicable) and quantity of the monitored drug Directions for use of the monitored drug Name and address of the prescriber Date monitored drug is prescribed The new requirements for prescribers to record on a prescription for a monitored drug their College registration number (e.g., CPSO number) and the patient s identification number and the type of patient identification provided (e.g., driver s licence, Ontario Photo Card, Health Card, etc.) is intended to improve the accuracy and completeness of the prescription information. Exemptions are permitted in limited cases where a patient is unable to provide any of the approved forms of identification. The prescriber should inform the patient that for the exemption to apply, the patient must personally pick up the monitored drug directly from the dispenser at the pharmacy or receive directly through the pharmacy s delivery service, if applicable. The patient cannot use an agent (e.g., family member, friend, etc.) or a third party mail or courier service (e.g., Fed Ex, Kinkos, Canada Post, etc.) to pick up or deliver, as applicable, the monitored drug. 6
7 Enactment of New Legislation For Dispensers: Must keep a record of the information on the prescription, which includes ensuring that the patient identifier is included on the patient s prescription and the prescriber s College registration number Require to record information on persons (agent) who pick up a prescription for a narcotic or controlled substance on behalf of the patient. This information would become part of the existing record-keeping requirements for dispensers and may be audited by the Ministry Once the narcotics monitoring system is implemented in Spring 2012, dispensers will be required to submit the information into the system as directed by the ministry 7
8 Narcotics Monitoring System As part of the strategy, the ministry is developing a narcotics monitoring database to collect information on narcotic prescriptions that are dispensed within Ontario including the private and public sector. The narcotics monitoring system will issue alerts at the time of dispense. Dispensers will use professional judgment to apply appropriate action, such as, do not fill or check with prescribers It is anticipated that the system will be able to identify patterns of inappropriate or excessive prescribing/dispensing, and to implement a province-wide system of alerts when attempts to visit multiple prescribers or visit multiple pharmacies are detected. It will help us target education programs to those areas where there may be a more immediate need due to potential inappropriate use, and make the prescribing, dispensing and use of narcotics and controlled substance medications safer and more secure. Prescribers will not have access to the narcotics monitoring system at this stage of the development. Prescriber access for patient prescription profile is part of the larger Medication Management System initiative. The current technology does not permit either the prescriber or the dispenser to access a patient profile. Other methods may be needed to be considered to facilitate the disclosure of the data that will be collected in the future. Implementation of the system is expected to be implemented in the early Spring Pharmacy systems have started to test their changes to prepare for implementation. The ministry will provide further communications to stakeholders to provide guidance relating to the submission requirements prior to the implementation date of the narcotics monitoring system 8
9 Other Initiatives Other initiatives include: A key component of the strategy is a series of educational initiatives for healthcare providers and the public. A phased approach to the launch of the initiatives has been initiated to allow for a targeted and focused development by leveraging existing resources. To date, the ministry has: provided a compilation of website resources on prescription narcotics and controlled substances for healthcare providers and the public. partnered with CAMH to provide the Addiction and Clinical Consultation Service telephone line for health care providers. The ministry is also working with other partners to ensure that the work for the narcotics strategy will align with the key areas identified in the First Nations Prescription Drug Abuse Strategy Report. This includes the education components as well as the collection of the information through the narcotics monitoring system. Some examples include: funding education workshops for health care providers in areas of the province where greater problems exist Exploring potential changes to formulary listings 9
10 Communications to Stakeholders The ministry has been working with our Communications and Information Branch team to disseminate the information to promote public awareness on the Narcotics Strategy and its new requirements. These include: updating information on the ministry website, including posting questions and answers issuing public notice ads in newspapers across Ontario providing tools, including posters and patient handouts, for health care providers (doctors, dentists and pharmacists) to help them inform their patients about the new requirements. Most health care providers have received the toolkits to date. providing a phone number to the government s ServiceOntario INFOline should people have further questions The ministry is engaging with key stakeholders to discuss the implementation plan and to respond to questions from stakeholders. To learn more about the Narcotics Strategy and the new legislative requirements, please visit the ministry website at: ontario.ca/narcoticsstrategy 10
11 QUESTIONS & ANSWERS 11
12 APPENDIX 12
13 Summary of Legislative Requirements for Monitored Drugs The legislation: Enables the Ministry to collect, use, and disclose information, including personal information and personal health information, that relates to the prescribing and dispensing of monitored drugs in Ontario. Requires prescribers to record specified information on prescriptions for monitored drugs. Requires dispensers to keep a record of specified information with respect to prescriptions for monitored drugs and to ensure that any identity verification requirements set out in the regulations are met prior to dispensing a monitored drug. Requires prescribers, dispensers and operators of pharmacies to disclose information related to prescriptions for monitored drugs to the Ministry as directed by the Ministry. Allows to Minister or the executive officer to disclose information related to prescriptions for monitored drugs to prescribers, dispensers and operators of pharmacies in specific circumstances. Creates offences and establish penalties for non-compliance with the Act. Requires public consultation on any proposed regulations affecting the collection, use or disclosure of personal information or personal health information under the Act. 13
14 Summary of Legislative Requirements for Monitored Drugs The regulation (Ontario Regulation 381/11): requires the prescriber to include an identifying number for the patient on a prescription for a narcotic or controlled substances specifies the information the dispenser must record when dispensing a narcotic or controlled substances specifies the type of identifying number that is acceptable i.e., government issued identification that bears the name of an individual and provides an acceptable level of certainty of the identity of the person the list will be approved by the Minister and posted on the Ministry website requires dispensers to record the name, address and identifier for persons who pick up a narcotic or controlled substance from the pharmacy provides exemptions to allow a prescription to be prescribed and dispensed if patients do not have appropriate identification ensures that all opioids (including those not currently listed in the Controlled Drug and Substances Act (Canada),) are monitored drugs in Ontario exempts prescribers in certain settings such as a hospitals or prisons from the requirements of the Narcotics Safety and Awareness Act, 2010 describes the content of public notices and the method of disclosure that would include: information to be collected, used and disclosed under the Narcotics Safety and Awareness Act, 2010 the purposes for collection, use and disclosure contact information for prescribers, dispensers and public 14
Ontario s Narcotics Strategy
Ontario Public Drug Program Division Ontario s Narcotics Strategy Frequently Asked Questions This fact sheet provides basic information only. It must not take the place of medical advice, diagnosis or
More informationOntario s Narcotics Strategy
Ontario Public Drug Programs Division Ontario s Narcotics Strategy Frequently Asked Questions This fact sheet provides basic information only. It must not take the place of medical advice, diagnosis or
More informationMinistry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference
Ministry of Health and Long-Term Care Presentation to the CPSO Methadone Prescribers Conference November 9, 2012 Overview Minister s Expert Working Group on Narcotic Addiction OxyNEO and OxyContin: Changes
More informationNotice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch
Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch Frequently Asked Questions 1. What is the new Health Network System feature
More informationNarcotics Monitoring System (NMS) Update
Narcotics Monitoring System (NMS) Update DISCLOSURE OF COMMERCIAL SUPPORT This program has received no financial or in-kind support. Potential for conflict(s) of interest: None Faculty/Presenter Disclosure
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-THIRD REGULAR SESSION April 25-27, 2018 México D.F., México OEA/Ser.L/XIV.2.63 CICAD/doc.2385/18 25 April 2018 Original: English THE OPIOID
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More informationHarm Reduction Program Enhancement Questions and Answers. Population and Public Health Division Ministry of Health and Long-Term Care
Harm Reduction Program Enhancement Questions and Answers Population and Public Health Division Ministry of Health and Long-Term Care Table of Contents General Questions... 3 Funding... 4 Local Opioid Response...
More informationRhode Island. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationSafe Prescribing and Dispensing of Controlled Drugs. Joint Guidance Medical Council and Pharmaceutical Society of Ireland
Safe Prescribing and Dispensing of Controlled Drugs Joint Guidance Medical Council and Pharmaceutical Society of Ireland Purpose of this Guidance Purpose of this Guidance This resource aims to facilitate
More informationSASKATCHEWAN METHADONE PROGRAM
College of Physicians and Surgeons of Saskatchewan SASKATCHEWAN METHADONE PROGRAM Annual Report 2014 Date submitted: 11 September, 2015 P a g e 2 Table of Contents ANNUAL REPORT 2014... 3 About the Methadone
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationLegalization of non-medical Cannabis OPSBA Update September 08, 2017
Legalization of non-medical Cannabis OPSBA Update September 08, 2017 Purpose To provide an update on the Ministry of Education s (EDU s) work in relation to the expected legalization and regulation of
More informationMinistry of Health and Long-Term Care Overdose Prevention Sites: User Guide for Applicants
Ministry of Health and Long-Term Care Overdose Prevention Sites: User Guide for Applicants Population and Public Health Division Ministry of Health and Long-Term Care January 2018 INTRODUCTION On November
More informationOPIOID EMERGENCY RESPONSE REGULATION
Province of Alberta PUBLIC HEALTH ACT OPIOID EMERGENCY RESPONSE REGULATION Alberta Regulation 99/2017 With amendments up to and including Alberta Regulation 87/2018 Office Consolidation Published by Alberta
More informationOpioids in the Community: Chronic pain, Palliative Care, and Addiction. Dr Ahmed Jakda September 2017
Opioids in the Community: Chronic pain, Palliative Care, and Addiction Dr Ahmed Jakda September 2017 Outline Context Background Action Delisting Highstrength Long- Acting Opioids Opioid use and prescribing
More informationVirginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationOpioid Policy Steering Committee: Prescribing Intervention--Exploring a Strategy for
This document is scheduled to be published in the Federal Register on 12/13/2017 and available online at https://federalregister.gov/d/2017-26785, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationTable of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004
OXYCONTIN TASK FORCE INTERIM REPORT January 30, 2004 Submitted to Hon. Elizabeth Marshall, Minister of Health & Community Services, Government of Newfoundland and Labrador Table of Contents INTRODUCTION
More informationReport to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp Minnesota Board of
More informationCannabis Legalization August 22, Ministry of Attorney General Ministry of Finance
Cannabis Legalization August 22, 2018 Ministry of Attorney General Ministry of Finance Federal Cannabis Legalization and Regulation The federal Cannabis Act received Royal Assent on June 21, 2018 and will
More informationRE: PROPOSED AMENDMENTS TO REGULATIONS TO THE CONTROLLED DRUGS AND SUBSTANCES ACT
November 8, 2017 Ms. Michelle Boudreau Director General Controlled Substances Directorate Office of Legislative and Regulatory Affairs Health Canada 150 Tunney s Pasture Driveway, Main Stats Building Address
More informationACCG Mental Health Summit
ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationPrescription Drug Monitoring Programs and Other State-Level Strategies
Prescription Drug Monitoring Programs and Other State-Level Strategies Interventions to Reduce Opioid-Related Harms: Misuse, Abuse, Addiction, and Overdose Tamara M. Haegerich, PhD Acting Associate Director
More informationProvider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting
Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting Baltimore, MD April 5, 2011 Massachusetts Department of Public Health MA Prescription Monitoring Program
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationPrescription Monitoring Program Center for Excellence, Brandeis University. April 10-12, 2012 Walt Disney World Swan Resort
Prescription Monitoring Program Center for Excellence, Brandeis University April 10-12, 2012 Walt Disney World Swan Resort Accepted Learning Objectives: 1. Explain the current capabilities and contributions
More informationSub. S.B. 119 As Passed by the Senate
AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,
More information1. When are dispensers able to provide publicly funded naloxone emergency kits for Ontarians?
Ontario Public Drug Programs Division Ontario Naloxone Program for Pharmacies (ONPP) Frequently Asked Questions for Pharmacy Dispensers: Providing Publicly Funded Naloxone Kits and Claims Submission Using
More informationORDER of the Minister of Health No. 269/2017 of 14 March 2017 on mandatory provision of medicinal product adequate and continuous supplies
ORDER of the Minister of Health No. 269/2017 of 14 March 2017 on mandatory provision of medicinal product adequate and continuous supplies ISSUING BODY: The Ministry of Health published in: the Official
More informationRe: Bill 33, Safeguarding our Communities Act (Fentanyl Patch for Patch Return Policy), 2015
November 30, 2015 Mr. Peter Tabuns Chair, Standing Committee on Social Policy 99 Wellesley Street West, Room 1405 Whitney Block Queen's Park Toronto, ON M7A 1A2 Dear Mr. Tabuns: Re: Bill 33, Safeguarding
More informationCOLORADO PRESCRIPTION DRUG MONITORING PROGRAM
COLORADO PRESCRIPTION DRUG MONITORING PROGRAM Harold Rogers Prescription Drug Monitoring Program West Regional Meeting Salt Lake City, Utah August 12 13, 2014 Tia Stakely, M.S. PDMP Administrator 2005
More informationDRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT
c t DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to September 22, 2014. It is intended
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationAddressing the Harms of Prescription Drugs in Canada
www.ccsa.ca www.cclt.ca Addressing the Harms of Prescription Drugs in Canada Innovations & Policy Solutions for Addressing Prescription Drug Abuse April 30, 2014 Rita Notarandrea, Canadian Centre on Substance
More informationMinnesota. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE. Dr. David Williams Chief Medical Officer of Health
ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE Dr. David Williams Chief Medical Officer of Health National opioid-related mortality data, 2016 (Health Canada) Provincial Overdose Coordinator
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationRequirements for Nurse Practitioners to Prescribe Buprenorphine-Naloxone (Suboxone):
Nurse Practitioner Change in Scope of Practice: Education and Practice Requirements for Nurse Practitioners (NPs) to Prescribe Buprenorphine-Naloxone (Suboxone) and Methadone On October 20 th, 2017, ARNNL
More informationImplementation: Public Hearing: Request for Comments (FDA-2017-N-6502)
March 16, 2018 via online submission: www.regulations.gov The Honorable Scott Gottlieb Commissioner Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Opioid Policy Steering
More informationPREFACE. Saskatchewan is participating in the Common Drug Review (CDR).
PREFACE OBJECTIVES The Drug Plan has been established to: provide coverage to Saskatchewan residents for quality pharmaceutical products of proven therapeutic effectiveness; reduce the direct cost of prescription
More information2017 PGIP Fact Sheet Electronic Prescribing of Controlled Substances (EPCS)
2017 PGIP Fact Sheet Electronic Prescribing of Controlled Substances (EPCS) Overview Value Partnerships, in conjunction with the Blue Cross Pharmacy team, has created the Electronic Prescribing of Controlled
More information2017 Legislative Policy Update
2017 Legislative Policy Update Aliyah N. Horton, CAE Executive Director Maryland Pharmacists Association Presentation Overview Maryland Pharmacists Association General highlights of the session Pharmacy-related
More informationMichigan Legislative and Regulatory Pharmacy Initiatives Update
Michigan Legislative and Regulatory Pharmacy Initiatives Update Michigan Association of Health Plans Summer Conference Carrie Germain, R.Ph. Health Alliance Plan Senior Director, Pharmacy, Quality and
More informationPsychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill
Psychoactive Substances (Increasing Penalty for Supply and Distribution) Amendment Bill 16 1 Report of the Justice Committee September 2018 Contents Recommendation... 2 About the bill as introduced...
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationNew Mexico. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationWithin the Scope of Practice/Role of _X APRN RN LPN CNA ADVISORY OPINION PAIN MANAGEMENT GUIDELIINES
Wyoming State Board of Nursing 130 Hobbs Avenue, Suite B Cheyenne, WY 82002 Phone (307) 777-7601 Fax (307) 777-3519 E-Mail: wsbn-info-licensing@wyo.gov Home Page: https://nursing-online.state.wy.us/ OPINION:
More informationMorrison County Community-Based Care Coordination. Our Core Values Reverence Integrity Compassion Excellence
Morrison County Community-Based Care Coordination Our Core Values Reverence Integrity Compassion Excellence Community Based Care Coordination Project The goal is to mitigate the need for, overuse of, and
More informationAppearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse
Opening Statement Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Dr. Chris Simpson, President-elect
More informationTennessee. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationLouisiana. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationKansas Department of Health and Environment (KDHE) Kansas Data-Driven Prevention Initiative Request for Proposal (RFP) Fiscal Year 2019
Kansas Department of Health and Environment (KDHE) Kansas Data-Driven Prevention Initiative Request for Proposal (RFP) Fiscal Year 2019 Kansas Department of Health and Environment Bureau of Health Promotion
More informationReport to the Legislature: Recommendations on Required Use and Other Uses of the MN Prescription Monitoring Program Database
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp Minnesota Board of
More informationMARYLAND BOARD OF PHARMACY
MARYLAND BOARD OF PHARMACY CONTRACEPTION REGULATIONSAnd Other Legislative Initiatives THE ROAD FROM CONCEPTUALIZATION TO IMPLEMENTATION Deena Speights-Napata Executive Director Maryland Board of Pharmacy
More informationOpportunities for Engaging Partners to Prevent Opioid Overdose-related Deaths
PREVENTION COLLABORATION IN ACTION Engaging the Right Partners Opportunities for Engaging Partners to Prevent Opioid Overdoserelated Deaths Preventing opioid overdose requires collaboration with a diverse
More informationMinistry of Children and Youth Services. Follow-up to VFM Section 3.01, 2013 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 4 Section 4.01 Ministry of Children and Youth Services Autism Services and Supports for Children Follow-up to VFM Section 3.01, 2013 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of
More informationResponding to BC s Opioid Overdose Epidemic
Responding to BC s Opioid Overdose Epidemic Progress Update September 2017 BACKGROUND Since BC s Public Health Emergency was declared in 2016, people across the province have mobilized to immediately respond
More informationGilberto Gerra. Drug Prevention and Health Branch
Operational Recommendations on ensuring the availability of and access to controlled substances exclusively for medical and scientific purposes, while preventing their diversion Gilberto Gerra Drug Prevention
More informationPartnered Efforts in Safe Opioid Prescribing
Partnered Efforts in Safe Opioid Prescribing On the Road with OntarioMD March 7, 2018 Dr. Kevin Samson 2 Partnered Efforts in Safe Opioid Prescribing On the Road with OntarioMD March 7, 2018 Dr. Kevin
More informationMinister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018
The Minister s Opioid Emergency Response Commission was established May 31, 2017 to support the Government of Alberta s urgent response to the opioid crisis. As part of its mandate, the Commission is responsible
More information1. Introduction. 2. Role of PSI as Pharmacy Regulator
1. Introduction 1.1. I would like to begin by thanking the Committee for inviting the Pharmaceutical Society of Ireland here today to assist in the Committee s on-going scrutiny of the Cannabis for Medicinal
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D SIXTY-FIRST REGULAR SESSION April 24-26, 2017 Washington, D.C. OEA/Ser.L/XIV.2.61 CICAD/doc.2299/17 21 April 2017 Original: English CANADA S OPIOID
More informationPrescription Monitoring Program (PMP)
06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid
More informationCommunity Engagement to Address the Opioid Crisis. Laura Palombi, PharmD, MPH, MAT, AE-C
Community Engagement to Address the Opioid Crisis Laura Palombi, PharmD, MPH, MAT, AE-C Presenter Information Assistant Professor at the University of Minnesota College of Pharmacy Affiliate Assistant
More informationIncrease in Opioid Related Deaths What the Data Can Tell us. Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes
Increase in Opioid Related Deaths What the Data Can Tell us Ontario Methadone Prescriber s Conference November 7, 2014 Tara Gomes Objectives Prescription Opioid Misuse and Abuse: How did we get here? Opioid
More informationTechnical Assistance Guide No Recommended PDMP Reports to Support Licensing/Regulatory Boards and Law Enforcement Investigations
Technical Assistance Guide No. 02-14 Recommended PDMP Reports to Support Licensing/Regulatory Boards and Law Enforcement Investigations This project was supported by Grant No. 2011-PM-BX-K001 awarded by
More informationService Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian
Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through
More informationREGULATORY IMPACT STATEMENT and COST-BENEFIT ANALYSIS (RISCBA)
State Budget Office Office of Regulatory Reinvention 111 S. Capitol Avenue; 8th Floor, Romney Building Lansing, MI 48933 Phone: (517) 335-8658 FAX: (517) 335-9512 REGULATORY IMPACT STATEMENT and COST-BENEFIT
More informationAccess to pain therapy in the UN resolutions: worldwide perspective
Access to pain therapy in the UN resolutions: worldwide perspective Elizabeth Mattfeld Drug Prevention and Health Branch The Single Convention recognizes the medical use of narcotic drugs as indispensable
More informationGuideline for the Rational Use of Controlled Drugs
Guideline for the Rational Use of Controlled Drugs Ministry of Health Male' Republic of Maldives April 2000 Table of Contents Page Introduction.. 2 1. Procurement and Supply of Controlled Drugs 3 1.1 Import
More informationNYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.
NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement May 2, 2018 1 May 2, 2018 2 Bureau Overview May 2, 2018 3 HISTORY 1850--Bureau
More informationCancer Care Ontario / Ontario Public Drug Programs
Cancer Care Ontario / Ontario Public Drug Programs Policy: Public funding of cancer drugs and their administration within the context of clinical trials Version: 3.0 Effective Date: December 12, 2016 Replaces
More informationPRESCRIBING GUIDELINES
Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy
More informationAlberta - US Comparator: Standard-Making and Enforcement Functions
Alberta - US Comparator: Standard-Making and Enforcement Functions Current Reliability Standards Below is a link to current reliability standards in Alberta: http://www.aeso.ca/rulesprocedures/17006.html
More informationWest Virginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile West Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationTemplate Standard Operating Procedure For: Handling of Midazolam and other controlled drugs in Dental Practices
Name of Dental Practice : Objectives To ensure implementation of the regulations and guidance on safe and secure handling of midazolam and other controlled drugs (CDs) Scope To cover all aspects of obtaining
More informationThe STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018
The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology
More informationCardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention
Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention The people of Cardinal Health care deeply about the devastation opioid abuse has caused American families and communities
More informationState-Level Strategies for Reducing Prescription Drug Overdose Deaths: Utah s Prescription Safety Programpme_
Pain Medicine 2011; 12: S66 S72 Wiley Periodicals, Inc. SECTION 2: FINDING SOLUTIONS State-Level Strategies for Reducing Prescription Drug Overdose Deaths: Utah s Prescription Safety Programpme_1126 66..72
More informationPosition No. Title Supervisor s Position Clinical Educator Executive Director Population Health
Page1 1. IDENTIFICATION Position No. Title Supervisor s Position 10-13487 Clinical Educator Executive Director Population Health Department Division/Region Community Location Health Population Health Iqaluit
More informationPrescribing and Dispensing Drugs
STANDARDS & GUIDELINES Prescribing and Dispensing Drugs TABLE OF CONTENTS Standards and guidelines inform practitioners and the public of CDSBC s expectations for registrants. This document primarily contains
More informationSeptember 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic
National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC 20036 RE: Prescription Opioid Epidemic On behalf of America s Health Insurance Plans (AHIP), thank you for your leadership
More informationRe: Handling of gabapentin and pregabalin as Schedule 3 Controlled Drugs in health and justice commissioned services
To: Health and justice commissioners and providers Public Health England health and justice leads Her Majesty s Prison and Probation Service Home Office immigration removal centre leads Health and justice
More informationInternational Drug Control Conventions. Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
18 October 2016 International Drug Control Conventions Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol Convention on Psychotropic Substances of 1971 United Nations Convention
More informationPreventing Opioid Misuse in Texas
Preventing Opioid Misuse in Texas Kasey Strey, ACPS, SPF-Rx Project Director Jessica Duncan Cance, MPH, PhD, TTOR Lead Purpose Provide an overview of HHSC -funded opioid misuse prevention activities Discuss
More informationMinistry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 1 Section 1.08 Ministry of Health and Long-Term Care Palliative Care Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of Actions Recommended Actions
More information11/11/2015. MVAs Suicide Firearms Homicide. Where Can I Find A Copy of the PDMP Law? Why Was the Law Established? Why Was the Law Established?
Where Can I Find A Copy of the PDMP Law? Alabama Uniform Controlled Substances Act Code of Alabama 1975 20-2- (Article 10) -210 through 220 and Rules 420-7-2-.11 through.13 1 Why Was the Law Established?
More informationHouse Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515
February 28, 2018 The Honorable Michael Burgess, M.D. The Honorable Gene Green Chairman Ranking Member Subcommittee on Health Subcommittee on Health House Committee on Energy and Commerce House Committee
More informationTitle of Session: Restricting the Marketing and Advertising of Opioids in Canada Date of Session: September 5, 2018
Title of Session: Restricting the Marketing and Advertising of Opioids in Canada Date of Session: September 5, 2018 Purpose To update stakeholders on Health Canada s actions to date, and to consult on
More informationI am pleased to highlight for this Honourable House and the public. that today the Government will be laying amendments to the
MINISTERIAL STATEMENT TO THE HOUSE OF ASSEMBLY BY THE HONOURABLE KIM N. WILSON, JP, MP MINISTER OF HEALTH UPDATES AND MODERNIZATION OF DRUG SCHEDULES 24 November 2017 Mr Speaker and Honourable Members,
More informationUS H.R.6 of the 115 th Congress of the United States Session
US H.R.6 of the 115 th Congress of the United States 2017-2018 Session This Act may be cited as the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
More informationPLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.
PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this Act, current to July 1, 2012. It is intended for information and reference purposes only. This
More informationCurbing Prescription Drug Abuse in Medicaid
Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance
More informationRisk Evaluation And Mitigation Strategies:
Risk Evaluation And Mitigation Strategies: The Experts Answer Questions from Health-System Pharmacists A midday symposium about the risk evaluation and mitigation strategies (REMS) required by the Food
More informationONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE
ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE Sean Court Director, Strategic Policy Branch Ministry of Health and Long-Term Care November 24, 2017 Strategy to Prevent Opioid Addiction and
More informationCORPORATE POLICY MANUAL. 1. SCOPE 1.1 Authority This policy is issued under the authority of the Senior Executive Team.
C-37 CANADORE COLLEGE CORPORATE POLICY MANUAL TITLE: Substance Use Policy Recreational Cannabis and Alcohol EFFECTIVE DATE: October 12, 2018 1. SCOPE 1.1 Authority This policy is issued under the authority
More informationStatement Of. The National Association of Chain Drug Stores. For. United States Senate Caucus on International Narcotics Control.
Statement Of The National Association of Chain Drug Stores For United States Senate Caucus on International Narcotics Control Hearing on: Improving Management 10:00 a.m. 226 Dirksen Senate Office Building
More informationControlled Substances: A survey of tools and resources required by hospital pharmacists
Controlled Substances: A survey of tools and resources required by hospital pharmacists TABLE OF CONTENTS 2018. Canadian Society of Hospital Pharmacists About the survey 1 The Short and Snappy 1 What CSHP
More information